project id: TCGA-PRAD; case submitter id: TCGA-EJ-A65M; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.75; rna integrity number: 8.2; age at index: 65; days to birth: -23767; ethnicity: not reported; gender: male; race: black or african american; vital status: Alive; year of birth: 1948; age at diagnosis: 23767; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 230.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 69; initial weight: 340.0; sample id: 4761d0f1-e6e9-4d8f-9fce-014c3f2ed64f; sample submitter id: TCGA-EJ-A65M-01A; portion id: 2daceaf1-a8d3-4f22-b782-94ee5650123a; portion submitter id: TCGA-EJ-A65M-01A-11; slide id: 2355218d-3ddc-401e-8b14-68e9a8d481d7; slide submitter id: TCGA-EJ-A65M-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 35.0; percent stromal cells: 0.0; percent tumor cells: 65.0; percent tumor nuclei: 65.0; section location: TOP;